StockStory flags stocks with weaknesses like slowing revenue, shrinking cash flow, and lofty valuations, while highlighting potential winners with steady growth and improving financials.
FDA approves second generic mifepristone, drawing criticism from anti-abortion groups despite the drug's long safety record.
StockStory flags stocks with weaknesses like slowing revenue, shrinking cash flow, and lofty valuations, while highlighting potential winners with steady growth and improving financials.
FDA approves second generic mifepristone, drawing criticism from anti-abortion groups despite the drug's long safety record.